RadNet, Inc. (RDNT) has a MoatMap StockRank of 24/100 based on Quality (38/100), Value (35/100), and Momentum (37/100) factor scores. The current signal is SELL. RadNet is the leading US provider of outpatient diagnostic imaging. It is a classic Peter Lynch 'boring but beautiful' business with highly visible consumer demand. RadNet is successfully integrating AI to dramatically improve radiologist productivity and scan throughput, creating a powerful scale-economics-shared model that will drive long-term margin expansion.
RadNet, Inc. is the largest provider of freestanding outpatient diagnostic imaging services in the United States, offering a comprehensive range of MRI, CT, PET/CT, mammography, and X-ray services. The company's competitive advantage lies in its expansive network of centers, significant scale, and integration of AI-powered solutions to enhance diagnostic accuracy and operational efficiency. It plays a critical role in delivering accessible and advanced imaging care.
| Price | $54.23 |
| Market Cap | $4.3B |
| P/E (Forward) | 55.98 |
| Price/Book | 3.75 |
| Return on Equity | 1.8% |
| Return on Invested Capital | 3.2% |
| Debt/Equity | 143.00 |
| Gross Margin | 17.2% |
| Operating Margin | -2.8% |
| Revenue Growth | 22.1% |
| Free Cash Flow | $190M |
RadNet, Inc. operates in the Diagnostics & Research industry, part of the Healthcare sector (United States).